PRF Technologies (PRFX) announced that its AI-driven GridFeed platform is exploring the AI and hyperscale data center market as a strategic growth opportunity. The company believes GridFeed’s existing energy optimization engine, currently used for renewable assets and battery storage, can be adapted to help data center operators maximize the value of limited power capacity as electricity and grid constraints intensify.Potential applications under evaluation include workload shifting, energy cost optimization, battery charge and discharge strategies, demand response and real-time power allocation. On September 9, 2026, PRF outlined plans to place GridFeed and DeepSolar into a standalone, wholly owned subsidiary, which it believes will give GridFeed more flexibility to pursue new markets and partnerships across the data center ecosystem.

YouTube video by Neobrane

PRF Technologies (PRFX) reported first half 2026 results and a broad business update across its healthcare and AI energy segments.In ophthalmology, the FDA cleared the IND for OcuRing™-K, enabling a U.S. multi-center Phase II cataract-surgery trial, with enrollment expected in the second half of 2026. In post-operative pain, PRF-110 showed sustained 72-hour analgesic activity comparable to ZYNRELEF® in a porcine model using a ropivacaine-only, NSAID-free formulation, with expanded data indicating slower systemic absorption and enhanced local tissue retention.In energy, the DeepSolar platform added commercial collaborations, validated its Predict™ optimization engine on real-world European data, expanded into battery storage and unveiled the GridFeed™ trading platform, and began generating revenue from SaaS and service engagements. As of June 30, 2026, cash and equivalents were approximately $11.6 million, supported by a $10.0 million equity raise, while R&D spending increased and G&A expenses declined 39% year-over-year.

PRF Technologies (Nasdaq: PRFX) reported in a shareholder letter that it raised $10 million on May 28, 2026 through its equity line facility, which the company says substantially strengthened its balance sheet and increased strategic flexibility for growth initiatives.The biotechnology subsidiary LayerBio is completing operational and clinical preparations for a planned Phase 2 trial of OcuRing-K, an ocular implant used during cataract surgery, while lead candidate PRF-110 showed expanded preclinical data with sustained 72-hour analgesic activity versus an approved extended-release benchmark.In renewable energy, DeepSolar validated its Predict platform with European market data, added Battery-to-Revenue Intelligence for storage assets, joined the NVIDIA Connect program and plans to showcase GridFeed at Energy Trading Week Europe 2026.

YouTube video by Really American

YouTube video by Really American

YouTube video by Really American

YouTube video by Really American

YouTube video by Really American

YouTube video by Really American

YouTube video by Really American

YouTube video by Really American

YouTube video by Really American

YouTube video by Really American

YouTube video by Really American

Real-world European market, weather and production data tested DeepSolar Predict across day-ahead and intraday scenarios ahead of planned launch.

PRF-110 showed similar mechanical-sensitivity reductions to ZYNRELEF in a porcine post-op pain model, plus higher local tissue retention.